aging

Exclusive By Megan Molteni

Anti-aging foundation’s CEO left amid an investigation of co-founder Aubrey de Grey

Health By Alicia Diaz

The decision to pull loved ones out of nursing homes when the pandemic hit was a great alternative — for those who could afford it 

Biotech By Megan Molteni

Anti-aging research pioneer Aubrey de Grey placed on leave over sexual harassment allegations

First Opinion By Laura Fraade-Blanar, Ryan Best and Vijeth Iyengar

Ridesharing can help older people be functionally independent in their homes, communities

First Opinion By Jason Resendez and Stephanie Monroe

Clinical research doesn’t reflect the Alzheimer’s population. That needs to change

STAT Summit By Elizabeth Cooney

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Biotech By Adam Feuerstein

FDA, under fire from critics, revises prescribing information for Biogen’s Alzheimer’s drug

First Opinion By Emil D. Kakkis

Aduhelm’s accelerated approval offers a promising roadmap for rare neurological diseases

First Opinion By Josh Marx

Outdated Medicare rules threaten older Americans’ access to home medical equipment

Pharmalot By Ed Silverman

Revised analysis nudges up cost-effective price for Biogen’s Alzheimer’s drug to $3,000 to $8,400 a year

Health By Nicholas St. Fleur

STAT+ Conversations: Can tech change in-home care for seniors?

First Opinion By Madhav Thambisetty

Why a controversial decision won’t stop me from serving on FDA advisory committees

First Opinion By Sam Gandy

6 ways the FDA’s approval of Aduhelm does more harm than good

First Opinion By Ken Marek

The approval of aducanumab isn’t the end of the story. It’s just the beginning

Health By Elizabeth Cooney

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

First Opinion By Dana Goldman and Darius Lakdawalla

FDA’s approval of aducanumab paves the way for ‘more momentous’ Alzheimer’s breakthroughs

First Opinion By Jim Taylor

Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark

First Opinion By Nora Super and Diane Ty

Routine cognitive screening can help detect early signs of dementia

In the Lab By Megan Molteni

Reawakened immune cells show promise in mice against zombie cells tied to diseases of aging

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Vaccine riches, patent waivers, & a gene therapy for aging

Exclusive By Megan Molteni

Six patients with dementia went to Mexico for an unproven gene therapy, a biotech CEO claims

First Opinion By Haider J. Warraich

For-profit nursing homes and hospices are a bad deal for older Americans

First Opinion Podcast By Patrick Skerrett

Jason Karlawish and an Alzheimer’s caregiver on dementia’s ripple effect

First Opinion By George Vradenburg and Jeffrey Cummings

Collaboration between the FDA and industry is essential to foster innovation in Alzheimer’s treatments

First Opinion By Jasmine L. Travers

We need long-term solutions for older Americans’ long-term care